Blue Jet HealthQ3 FY24

Blue Jet Health Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹510.6P/E: 33.9Market Cap: ₹9.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Contrast media business is expected to see growth from Q2/Q3 FY25 with approvals and marketing efforts stabilizing in the US and Europe.
  • New contrast media product validation expected this quarter, with commercial volumes ramping up from Q2/Q3 FY25.
  • Pharmaceutical intermediate (PI API) segment, particularly for the cardiovascular drug with patent protection till 2030, is projected to grow significantly with commercial capacity increasing from Q1 FY25.
  • Artificial sweetener business faces short-term challenges due to Chinese dumping; focus is shifting to long-term CDMO customers, new sweeteners, and expanding customer base for recovery over 12-18 months.
  • Backward integration and capex in Mahad and Ambernath units are expected to provide stability and support growth in advanced intermediates and CDMO opportunities.
  • Conservative revenue growth estimates are maintained with potential for aggressive catch-up post-capex stabilization.
  • Overall, medium-term revenue growth is anticipated with capacity ramp-ups and product launches aligned to FY25 and FY26 timelines.

See what Blue Jet Health management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The document does not explicitly mention any current or upcoming fundraising plans through debt or equity.
  • Capex plans for FY24 and FY25 are detailed (INR 160 crores in FY24 and around INR 200-220 crores in FY25), funded likely through internal resources and cash investments (INR 237 crores as of December 31).
  • No specific mention of raising funds via equity or debt in the Q3 FY24 earnings call or in management comments.
  • Focus appears to be on utilizing cash balances and project-specific investments rather than external fundraising currently.
  • Any future capital raises, if planned, are not disclosed in the provided content from this earnings call.

See what Blue Jet Health management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Mahad site: INR 250 crores capex split between FY24 and FY25; includes two blocks:
  • - Backward integration block for raw materials (planned completion by Q3 FY25)
  • - Multiproduct intermediate block for CDMO opportunities (cardiovascular, CNS, oncology)
  • - Significant portion allocated to utilities and infrastructure upgrades
  • Ambernath Unit 2: INR 90-100 crores capex nearly complete by March-April 2024; capacity ready for validation in Q1 FY25
  • Greenfield site: EC application in progress; accelerated investments expected, with facility operational by FY26
  • Solar project: INR 30 crores invested; over 60% of power requirement expected from renewable sources for cost savings
  • Continued R&D expansion to support pipeline growth in contrast media, pharma intermediates, and artificial sweeteners

Track Blue Jet Health — get its next earnings analysis in your feed

How does Blue Jet Health rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisBlue Jet Health
Rev 3Mar 4

How does Blue Jet Health rank in Pharmaceuticals & Biotechnology?

Compare Blue Jet Health against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →